Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Beilstein J Org Chem ; 9: 15-25, 2013.
Article in English | MEDLINE | ID: mdl-23400640

ABSTRACT

Inhibition of the Trypanosoma cruzi cysteine protease cruzain has been proposed as a therapeutic approach for the treatment of Chagas' disease. Among the best-studied cruzain inhibitors to date is the vinylsulfone K777 (1), which has proven effective in animal models of Chagas' disease. Recent structure-activity studies aimed at addressing potential liabilities of 1 have now produced analogues such as N-[(2S)-1-[[(E,3S)-1-(benzenesulfonyl)-5-phenylpent-1-en-3-yl]amino]-3-(4-methylphenyl)-1-oxopropan-2-yl]pyridine-4-carboxamide (4), which is trypanocidal at ten-fold lower concentrations than for 1. We now find that the trypanocidal activity of 4 derives primarily from the inhibition of T. cruzi 14-α-demethylase (TcCYP51), a cytochrome P450 enzyme involved in the biosynthesis of ergosterol in the parasite. Compound 4 also inhibits mammalian CYP isoforms but is trypanocidal at concentrations below those required to significantly inhibit mammalian CYPs in vitro. A chemical-proteomics approach employing an activity-based probe derived from 1 was used to identify mammalian cathepsin B as a potentially important off-target of 1 and 4. Computational docking studies and the evaluation of truncated analogues of 4 reveal structural determinants for TcCYP51 binding, information that will be useful in further optimization of this new class of inhibitors.

2.
PLoS Pathog ; 7(9): e1002139, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21909255

ABSTRACT

Trypanosoma cruzi is the causative agent of Chagas' disease. Novel chemotherapy with the drug K11777 targets the major cysteine protease cruzain and disrupts amastigote intracellular development. Nevertheless, the biological role of the protease in infection and pathogenesis remains unclear as cruzain gene knockout failed due to genetic redundancy. A role for the T. cruzi cysteine protease cruzain in immune evasion was elucidated in a comparative study of parental wild type- and cruzain-deficient parasites. Wild type T. cruzi did not activate host macrophages during early infection (<60 min) and no increase in ∼P iκB was detected. The signaling factor NF-κB P65 colocalized with cruzain on the cell surface of intracellular wild type parasites, and was proteolytically cleaved. No significant IL-12 expression occurred in macrophages infected with wild type T. cruzi and treated with LPS and BFA, confirming impairment of macrophage activation pathways. In contrast, cruzain-deficient parasites induced macrophage activation, detectable iκB phosphorylation, and nuclear NF-κB P65 localization. These parasites were unable to develop intracellularly and survive within macrophages. IL 12 expression levels in macrophages infected with cruzain-deficient T. cruzi were comparable to LPS activated controls. Thus cruzain hinders macrophage activation during the early (<60 min) stages of infection, by interruption of the NF-κB P65 mediated signaling pathway. These early events allow T. cruzi survival and replication, and may lead to the spread of infection in acute Chagas' disease.


Subject(s)
Cysteine Endopeptidases/physiology , Immune Evasion/physiology , Macrophages/parasitology , Protozoan Proteins/physiology , Animals , Arginase/biosynthesis , Cysteine Endopeptidases/deficiency , Dipeptides/pharmacology , Humans , I-kappa B Proteins/metabolism , Interleukin-12/biosynthesis , Lipopolysaccharides/pharmacology , Macrophage Activation/drug effects , Macrophages/drug effects , Macrophages/metabolism , Mice , NF-kappa B/metabolism , Phenylalanine/analogs & derivatives , Piperazines , Tosyl Compounds , Trypanosoma cruzi/drug effects , Trypanosoma cruzi/genetics , Vinyl Compounds/pharmacology
3.
PLoS Negl Trop Dis ; 4(9)2010 Sep 14.
Article in English | MEDLINE | ID: mdl-20856868

ABSTRACT

BACKGROUND: Cruzain, the major cysteine protease of Trypanosoma cruzi, is an essential enzyme for the parasite life cycle and has been validated as a viable target to treat Chagas' disease. As a proof-of-concept, K11777, a potent inhibitor of cruzain, was found to effectively eliminate T. cruzi infection and is currently a clinical candidate for treatment of Chagas' disease. METHODOLOGY/PRINCIPAL FINDINGS: WRR-483, an analog of K11777, was synthesized and evaluated as an inhibitor of cruzain and against T. cruzi proliferation in cell culture. This compound demonstrates good potency against cruzain with sensitivity to pH conditions and high efficacy in the cell culture assay. Furthermore, WRR-483 also eradicates parasite infection in a mouse model of acute Chagas' disease. To determine the atomic-level details of the inhibitor interacting with cruzain, a 1.5 A crystal structure of the protease in complex with WRR-483 was solved. The structure illustrates that WRR-483 binds covalently to the active site cysteine of the protease in a similar manner as other vinyl sulfone-based inhibitors. Details of the critical interactions within the specificity binding pocket are also reported. CONCLUSIONS: We demonstrate that WRR-483 is an effective cysteine protease inhibitor with trypanocidal activity in cell culture and animal model with comparable efficacy to K11777. Crystallographic evidence confirms that the mode of action is by targeting the active site of cruzain. Taken together, these results suggest that WRR-483 has potential to be developed as a treatment for Chagas' disease.


Subject(s)
Antiprotozoal Agents/administration & dosage , Antiprotozoal Agents/pharmacology , Chagas Disease/drug therapy , Cysteine Proteinase Inhibitors/administration & dosage , Cysteine Proteinase Inhibitors/pharmacology , Oligopeptides/administration & dosage , Oligopeptides/pharmacology , Sulfones/administration & dosage , Sulfones/pharmacology , Trypanosoma cruzi/drug effects , Animals , Antiprotozoal Agents/chemical synthesis , Antiprotozoal Agents/metabolism , Catalytic Domain , Crystallography, X-Ray , Cysteine Endopeptidases/chemistry , Cysteine Endopeptidases/metabolism , Cysteine Proteinase Inhibitors/chemical synthesis , Cysteine Proteinase Inhibitors/metabolism , Dipeptides/administration & dosage , Dipeptides/chemical synthesis , Dipeptides/metabolism , Dipeptides/pharmacology , Disease Models, Animal , Female , Mice , Mice, Inbred C3H , Models, Molecular , Oligopeptides/chemical synthesis , Oligopeptides/metabolism , Parasitic Sensitivity Tests , Protein Binding , Protein Structure, Tertiary , Protozoan Proteins/chemistry , Protozoan Proteins/metabolism , Sulfones/chemical synthesis , Sulfones/metabolism , Treatment Outcome , Vinyl Compounds/administration & dosage , Vinyl Compounds/chemical synthesis , Vinyl Compounds/metabolism , Vinyl Compounds/pharmacology
4.
Antimicrob Agents Chemother ; 54(8): 3326-34, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20547819

ABSTRACT

Chagas' disease, caused by infection with the parasite Trypanosoma cruzi, is the major cause of heart failure in Latin America. Classic clinical manifestations result from the infection of heart muscle cells leading to progressive cardiomyopathy. To ameliorate disease, chemotherapy must eradicate the parasite. Current drugs are ineffective and toxic, and new therapy is a critical need. To expedite drug screening for this neglected disease, we have developed and validated a cell-based, high-throughput assay that can be used with a variety of untransfected T. cruzi isolates and host cells and that simultaneously measures efficacy against the intracellular amastigote stage and toxicity to host cells. T. cruzi-infected muscle cells were incubated in 96-well plates with test compounds. Assay plates were automatically imaged and analyzed based on size differences between the DAPI (4',6-diamidino-2-phenylindole)-stained host cell nuclei and parasite kinetoplasts. A reduction in the ratio of T. cruzi per host cell provided a quantitative measure of parasite growth inhibition, while a decrease in count of the host nuclei indicated compound toxicity. The assay was used to screen a library of clinically approved drugs and identified 55 compounds with activity against T. cruzi. The flexible assay design allows the use of various parasite strains, including clinical isolates with different biological characteristics (e.g., tissue tropism and drug sensitivity), and a broad range of host cells and may even be adapted to screen for inhibitors against other intracellular pathogens. This high-throughput assay will have an important impact in antiparasitic drug discovery.


Subject(s)
Drug Evaluation, Preclinical/methods , Hepatocytes/parasitology , High-Throughput Screening Assays/methods , Image Processing, Computer-Assisted/methods , Muscle, Skeletal/parasitology , Trypanocidal Agents/pharmacology , Trypanosoma cruzi/drug effects , Animals , Cattle , Cell Line , Cell Line, Tumor , Chagas Disease/drug therapy , Chagas Disease/parasitology , Hepatocytes/cytology , Hepatocytes/ultrastructure , Humans , Muscle, Skeletal/cytology , Muscle, Skeletal/ultrastructure , Parasitic Sensitivity Tests , Trypanosoma cruzi/growth & development
5.
Antimicrob Agents Chemother ; 54(6): 2480-8, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20385875

ABSTRACT

Chagas' disease, the leading cause of heart failure in Latin America, is caused by the kinetoplastid protozoan Trypanosoma cruzi. The sterols of T. cruzi resemble those of fungi, both in composition and in biosynthesis. Azole inhibitors of sterol 14alpha-demethylase (CYP51) successfully treat fungal infections in humans, and efforts to adapt the success of antifungal azoles posaconazole and ravuconazole as second-use agents for Chagas' disease are under way. However, to address concerns about the use of azoles for Chagas' disease, including drug resistance and cost, the rational design of nonazole CYP51 inhibitors can provide promising alternative drug chemotypes. We report the curative effect of the nonazole CYP51 inhibitor LP10 in an acute mouse model of T. cruzi infection. Mice treated with an oral dose of 40 mg LP10/kg of body weight twice a day (BID) for 30 days, initiated 24 h postinfection, showed no signs of acute disease and had histologically normal tissues after 6 months. A very stringent test of cure showed that 4/5 mice had negative PCR results for T. cruzi, and parasites were amplified by hemoculture in only two treated mice. These results compare favorably with those reported for posaconazole. Electron microscopy and gas chromatography-mass spectrometry (GC-MS) analysis of sterol composition confirmed that treatment with LP10 blocked the 14alpha-demethylation step and induced breakdown of parasite cell membranes, culminating in severe ultrastructural and morphological alterations and death of the clinically relevant amastigote stage of the parasite.


Subject(s)
Aminopyridines/pharmacology , Antiprotozoal Agents/pharmacology , Chagas Disease/drug therapy , Cytochrome P-450 Enzyme Inhibitors , Enzyme Inhibitors/pharmacology , Indoles/pharmacology , Protozoan Proteins/antagonists & inhibitors , Trypanosoma cruzi/drug effects , Trypanosoma cruzi/enzymology , Aminopyridines/administration & dosage , Aminopyridines/chemistry , Animals , Antiprotozoal Agents/administration & dosage , Antiprotozoal Agents/chemistry , Catalytic Domain , Chagas Disease/parasitology , Cytochrome P-450 Enzyme System/chemistry , Disease Models, Animal , Enzyme Inhibitors/administration & dosage , Enzyme Inhibitors/chemistry , Female , Humans , Indoles/administration & dosage , Indoles/chemistry , Mice , Mice, Inbred C3H , Microscopy, Electron, Transmission , Models, Molecular , Protozoan Proteins/chemistry , Recombinant Proteins/antagonists & inhibitors , Recombinant Proteins/chemistry , Sterols/biosynthesis , Trypanosoma cruzi/ultrastructure
6.
J Med Chem ; 53(4): 1763-73, 2010 Feb 25.
Article in English | MEDLINE | ID: mdl-20088534

ABSTRACT

A century after discovering that the Trypanosoma cruzi parasite is the etiological agent of Chagas disease, treatment is still plagued by limited efficacy, toxicity, and the emergence of drug resistance. The development of inhibitors of the major T. cruzi cysteine protease, cruzain, has been demonstrated to be a promising drug discovery avenue for this neglected disease. Here we establish that a nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitor substantially ameliorates symptoms of acute Chagas disease in a mouse model with no apparent toxicity. A high-resolution crystal structure confirmed the mode of inhibition and revealed key binding interactions of this novel inhibitor class. Subsequent structure-guided optimization then resulted in inhibitor analogues with improvements in potency despite minimal or no additions in molecular weight. Evaluation of the analogues in cell culture showed enhanced activity. These results suggest that nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors have the potential to fulfill the urgent need for improved Chagas disease chemotherapy.


Subject(s)
Chagas Disease/drug therapy , Ketones/chemical synthesis , Protozoan Proteins/antagonists & inhibitors , Trypanocidal Agents/chemical synthesis , Animals , Cattle , Cells, Cultured , Cysteine Endopeptidases , Female , Ketones/chemistry , Ketones/pharmacology , Macrophages/drug effects , Macrophages/parasitology , Mice , Mice, Inbred C3H , Models, Molecular , Parasitic Sensitivity Tests , Quinolines/chemical synthesis , Quinolines/chemistry , Quinolines/pharmacology , Stereoisomerism , Structure-Activity Relationship , Triazoles/chemical synthesis , Triazoles/chemistry , Triazoles/pharmacology , Trypanocidal Agents/chemistry , Trypanocidal Agents/pharmacology , Trypanosoma cruzi/drug effects
7.
J Med Chem ; 53(1): 52-60, 2010 Jan 14.
Article in English | MEDLINE | ID: mdl-19908842

ABSTRACT

Trypanosoma cruzi and Trypanosoma brucei are parasites that cause Chagas' disease and African sleeping sickness, respectively. Both parasites rely on essential cysteine proteases for survival: cruzain for T. cruzi and TbCatB/rhodesain for T. brucei. A recent quantitative high-throughput screen of cruzain identified triazine nitriles, which are known inhibitors of other cysteine proteases, as reversible inhibitors of the enzyme. Structural modifications detailed herein, including core scaffold modification from triazine to purine, improved the in vitro potency against both cruzain and rhodesain by 350-fold, while also gaining activity against T. brucei parasites. Selected compounds were screened against a panel of human cysteine and serine proteases to determine selectivity, and a cocrystal was obtained of our most potent analogue bound to cruzain.


Subject(s)
Cysteine Endopeptidases/metabolism , Cysteine Proteinase Inhibitors/pharmacology , Protozoan Proteins/antagonists & inhibitors , Purines/pharmacology , Triazines/pharmacology , Trypanosoma/enzymology , Cysteine Proteinase Inhibitors/chemical synthesis , Cysteine Proteinase Inhibitors/chemistry , High-Throughput Screening Assays , Microbial Sensitivity Tests , Molecular Conformation , Purines/chemical synthesis , Purines/chemistry , Structure-Activity Relationship , Triazines/chemical synthesis , Triazines/chemistry , Trypanosoma/drug effects , Trypanosoma brucei brucei/drug effects , Trypanosoma brucei brucei/enzymology , Trypanosoma cruzi/drug effects , Trypanosoma cruzi/enzymology
8.
PLoS Negl Trop Dis ; 3(2): e372, 2009.
Article in English | MEDLINE | ID: mdl-19190730

ABSTRACT

BACKGROUND: The two front-line drugs for chronic Trypanosoma cruzi infections are limited by adverse side-effects and declining efficacy. One potential new target for Chagas' disease chemotherapy is sterol 14alpha-demethylase (CYP51), a cytochrome P450 enzyme involved in biosynthesis of membrane sterols. METHODOLOGY/PRINCIPAL FINDING: In a screening effort targeting Mycobacterium tuberculosis CYP51 (CYP51(Mt)), we previously identified the N-[4-pyridyl]-formamide moiety as a building block capable of delivering a variety of chemotypes into the CYP51 active site. In that work, the binding modes of several second generation compounds carrying this scaffold were determined by high-resolution co-crystal structures with CYP51(Mt). Subsequent assays against the CYP51 orthologue in T. cruzi, CYP51(Tc), demonstrated that two of the compounds tested in the earlier effort bound tightly to this enzyme. Both were tested in vitro for inhibitory effects against T. cruzi and the related protozoan parasite Trypanosoma brucei, the causative agent of African sleeping sickness. One of the compounds had potent, selective anti-T. cruzi activity in infected mouse macrophages. Cure of treated host cells was confirmed by prolonged incubation in the absence of the inhibiting compound. Discrimination between T. cruzi and T. brucei CYP51 by the inhibitor was largely based on the variability (phenylalanine versus isoleucine) of a single residue at a critical position in the active site. CONCLUSIONS/SIGNIFICANCE: CYP51(Mt)-based crystal structure analysis revealed that the functional groups of the two tightly bound compounds are likely to occupy different spaces in the CYP51 active site, suggesting the possibility of combining the beneficial features of both inhibitors in a third generation of compounds to achieve more potent and selective inhibition of CYP51(Tc).


Subject(s)
Cytochrome P-450 Enzyme Inhibitors , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/therapeutic use , Mycobacterium tuberculosis/enzymology , Trypanocidal Agents/pharmacology , Trypanocidal Agents/therapeutic use , Trypanosoma cruzi , Animals , Cattle , Cell Survival/drug effects , Cells, Cultured , Chagas Disease/drug therapy , Chagas Disease/parasitology , Cytochrome P-450 Enzyme System , Enzyme Inhibitors/adverse effects , Humans , Inhibitory Concentration 50 , Mice , Mycobacterium tuberculosis/drug effects , Parasitic Sensitivity Tests , Trypanocidal Agents/adverse effects , Trypanosoma cruzi/drug effects , Trypanosoma cruzi/enzymology
9.
J Inorg Biochem ; 102(10): 1839-45, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18684510

ABSTRACT

The cysteine proteases of the trypanosomatid parasitic protozoa have been validated as targets for chemotherapy of Chagas' disease and leishmaniasis. Metal complexes of gold, platinum, iridium, palladium, rhodium and osmium have been reported to have activity against a variety of trypanosomatids, but the molecular target of these compounds has not been defined. The activity of gold(III) and palladium(II) cyclometallated complexes, and oxorhenium(V) complexes against mammalian and parasitic cysteine proteases was investigated. All gold(III) complexes (1-6) inhibited cathepsin B with IC(50) values in the range of 0.2-1.4 microM. Of the six palladium compounds, aceto[2,6-bis[(butylthio-kappa S)methyl]phenyl-kappa C]-, (SP-4-3)-palladium(II) (11) was the most potent inhibitor of cathepsin B with an IC(50) of 0.4 microM. A clear structure-activity relationship was observed with the oxorhenium(V) complexes with chloro[2,2'-(thio-kappa S)bis[ethanethiolato-kappa S)]] oxorhenium(V) (16) being the most potent inhibitor of cathepsin B with an IC(50) of 0.009 microM. Six complexes were further tested against the parasite cysteine proteases, cruzain from T. cruzi, and cpB from L. major; the most potent inhibitors were the two rhenium complexes (2(1H)-pyridinethionato-kappa S(2))[2,6-bis[(mercapto-kappa S)methyl]pyridine-kappa N(1)] oxorhenium(V) (15) and chloro[2,2'-(thio-kappa S)bis[ethanethiolato-kappa S)]] oxorhenium(V) (16). The compounds were also evaluated in assays for parasite growth. Two oxorhenium(V) compounds ((p-methoxyphenylthiolato-S)[2,6-bis[(mercapto-kappa S)methyl]pyridine-kappa N(1)] oxorhenium(V) (14) and (methanethiolato)[2,2'-(thio-kappa S)bis[ethanethiolato-kappa S)]] oxorhenium (V) (18)) and the palladium compound 11 inhibited T. cruzi intracellular growth, and compound 11 inhibited promastigote growth in three Leishmania species. In conclusion this preliminary data indicates that metal complexes targeted at parasite cysteine proteases show promise for the treatment of both Chagas' disease and leishmaniasis.


Subject(s)
Cathepsin B/metabolism , Chagas Disease/drug therapy , Cysteine Proteinase Inhibitors/pharmacology , Leishmania/drug effects , Leishmaniasis/drug therapy , Metals/pharmacology , Trypanocidal Agents/pharmacology , Trypanosoma/drug effects , Animals , Cathepsin B/antagonists & inhibitors , Cysteine Endopeptidases/metabolism , Cysteine Proteinase Inhibitors/therapeutic use , Humans , Inorganic Chemicals/chemistry , Inorganic Chemicals/pharmacology , Metals/therapeutic use , Trypanocidal Agents/therapeutic use
10.
Curr Pharm Des ; 14(9): 889-900, 2008.
Article in English | MEDLINE | ID: mdl-18473838

ABSTRACT

Lysosomes were first described as vacuolar structures containing various hydrolytic enzymes at acidic pH. Subsequent studies revealed that the lysosome/vacuolar system is complex and composed of distinct membrane-enclosed vesicles including endosomes, primary and mature lysosomes, autophagic vesicles, residual bodies, multivesicular bodies, and digestive lysosomes. Lysosomes express a battery of hydrolytic enzymes including proteases, acid phosphatases, glycosidases, and lipases. Parasitic protozoa also possess complex intracellular lysosomes/endosomes/vesicles involved in digestion, transport and recycling of molecules similar to those of mammalian cells. Unique characteristics are ascribed to lysosomes of different parasites and may even differ between parasite stages. Transport of hydrolases and proteins to parasite lysosomes is directed either from the Golgi complex via endosomal vesicles or from endocytic vesicles originated in the cell surface. Inhibition of lysosomal proteases demonstrated that different proteolytic machineries catabolize distinct classes of proteins, and this selectivity may be exploited for the development of effective antiparasitic drugs. This review describes lysosomal molecules that are either validated or potential drug targets for Chagas' disease, sleeping sickness, leishmaniasis, toxoplasmosis, malaria, amebiasis, and giardiasis.


Subject(s)
Eukaryota/drug effects , Lysosomes/drug effects , Protozoan Infections/drug therapy , Animals , Antiprotozoal Agents/pharmacology , Drug Delivery Systems , Eukaryota/metabolism , Humans , Lysosomes/enzymology , Lysosomes/metabolism
11.
J Am Chem Soc ; 130(20): 6404-10, 2008 May 21.
Article in English | MEDLINE | ID: mdl-18435536

ABSTRACT

Cruzain is the major cysteine protease of Trypanosoma cruzi, which is the causative agent of Chagas disease and is a promising target for the development of new chemotherapy. With the goal of developing potent nonpeptidic inhibitors of cruzain, the substrate activity screening (SAS) method was used to screen a library of protease substrates initially designed to target the homologous human protease cathepsin S. Structure-based design was next used to further improve substrate cleavage efficiency by introducing additional binding interactions in the S3 pocket of cruzain. The optimized substrates were then converted to inhibitors by the introduction of cysteine protease mechanism-based pharmacophores. Inhibitor 38 was determined to be reversible even though it incorporated the vinyl sulfone pharmacophore that is well documented to give irreversible cruzain inhibition for peptidic inhibitors. The previously unexplored beta-chloro vinyl sulfone pharmacophore provided mechanistic insight that led to the development of potent irreversible acyl- and aryl-oxymethyl ketone cruzain inhibitors. For these inhibitors, potency did not solely depend on leaving group p K a, with 2,3,5,6-tetrafluorophenoxymethyl ketone 54 identified as one of the most potent inhibitors with a second-order inactivation constant of 147,000 s (-1) M (-1). This inhibitor completely eradicated the T. cruzi parasite from mammalian cell cultures and consequently has the potential to lead to new chemotherapeutics for Chagas disease.


Subject(s)
Cysteine Proteinase Inhibitors/chemistry , Cysteine Proteinase Inhibitors/pharmacology , Ketones/chemistry , Ketones/pharmacology , Protozoan Proteins/antagonists & inhibitors , Amino Acid Sequence , Animals , Cathepsins/chemistry , Cathepsins/metabolism , Cathepsins/pharmacology , Coumarins/chemistry , Coumarins/metabolism , Cysteine Endopeptidases/chemistry , Cysteine Endopeptidases/metabolism , Cysteine Proteinase Inhibitors/metabolism , Drug Design , Ketones/metabolism , Macrophages/parasitology , Mice , Molecular Sequence Data , Protozoan Proteins/chemistry , Protozoan Proteins/metabolism , Sequence Alignment , Structure-Activity Relationship , Sulfones/chemistry , Sulfones/metabolism , Sulfones/pharmacology , Triazoles , Trypanosoma cruzi/drug effects , Trypanosoma cruzi/enzymology
12.
Bioorg Med Chem Lett ; 18(2): 624-8, 2008 Jan 15.
Article in English | MEDLINE | ID: mdl-18055204

ABSTRACT

A systematic study of P2 and P3 substitution in a series of vinyl sulfone cysteine protease inhibitors is described. The introduction of a methyl substituent in the P2 phenylalanine aryl ring had a favorable effect on protease inhibition and conferred modest selectivity for rhodesain over cruzain. Rhodesain selectivity could be enhanced further by combining these P2 modifications with certain P3 amide substituents.


Subject(s)
Cysteine Proteinase Inhibitors/chemistry , Cysteine Proteinase Inhibitors/pharmacology , Ethylenes/chemistry , Ethylenes/pharmacology , Sulfonic Acids/chemistry , Sulfonic Acids/pharmacology , Trypanocidal Agents/chemistry , Trypanocidal Agents/pharmacology , Trypanosoma/drug effects , Animals , Structure-Activity Relationship , Trypanosoma/enzymology
13.
Antimicrob Agents Chemother ; 51(11): 3932-9, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17698625

ABSTRACT

Chagas' disease, caused by the parasite Trypanosoma cruzi, remains the leading cause of cardiopathy in Latin America with about 12 million people infected. Classic clinical manifestations derive from infection of muscle cells leading to progressive cardiomyopathy, while some patients develop megacolon or megaesophagus. A very aggressive clinical course including fulminant meningoencephalitis has been reported in patients who contract Chagas' disease in the background of immunodeficiency. This includes patients with human immunodeficiency virus infection as well as patients receiving immunosuppressive therapy for organ transplant. Currently, only two drugs are approved for the treatment of Chagas' disease, nifurtimox and benznidazole. Both have significant limitations due to common and serious side effects as well as limited availability. A promising group of new drug leads for Chagas' disease is cysteine protease inhibitors targeting cruzain, the major protease of T. cruzi. The inhibitor N-methyl-Pip-F-homoF-vinyl sulfonyl phenyl (N-methyl-Pip-F-hF-VS phi) is in late-stage preclinical development. Therefore, the question arose as to whether protease inhibitors targeting cruzain would have efficacy in Chagas' disease occurring in the background of immunodeficiency. To address this question, we studied the course of infection in recombinase-deficient (Rag1(-/-)) and normal mice infected with T. cruzi. Infections localized to heart and skeletal muscle in untreated normal animals, while untreated Rag1(-/-) mice showed severe infection in all organs and predominantly in liver and spleen. Treatment with the dipeptide N-methyl-Pip-F-hF-VS phi rescued immunodeficient animals from lethal Chagas' infection. The majority (60 to 100%) of inhibitor-treated Rag1(-/-) mice had increased survival, negative PCR, and normal tissues by histopathological examination.


Subject(s)
Chagas Disease/drug therapy , Cysteine Proteinase Inhibitors/pharmacology , Homeodomain Proteins/genetics , Trypanosoma cruzi/drug effects , Animals , Cattle , Cells, Cultured , Chagas Disease/genetics , Chagas Disease/pathology , Cysteine Endopeptidases , Disease Models, Animal , Female , Homeodomain Proteins/metabolism , Humans , Mice , Mice, Inbred C3H , Mice, Inbred C57BL , Mice, Knockout , Nifurtimox/pharmacology , Nitroimidazoles/pharmacology , Protozoan Proteins/antagonists & inhibitors , Survival Analysis , Trypanocidal Agents/pharmacology
14.
Antimicrob Agents Chemother ; 51(6): 2164-72, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17371810

ABSTRACT

Parasitic diseases are of enormous public health significance in developing countries-a situation compounded by the toxicity of and resistance to many current chemotherapeutics. We investigated a focused library of 18 structurally diverse bis-acridine compounds for in vitro bioactivity against seven protozoan and one helminth parasite species and compared the bioactivities and the cytotoxicities of these compounds toward various mammalian cell lines. Structure-activity relationships demonstrated the influence of both the bis-acridine linker structure and the terminal acridine heterocycle on potency and cytotoxicity. The bioactivity of polyamine-linked acridines required a minimum linker length of approximately 10 A. Increasing linker length resulted in bioactivity against most parasites but also cytotoxicity toward mammalian cells. N alkylation, but less so N acylation, of the polyamine linker ameliorated cytotoxicity while retaining bioactivity with 50% effective concentration (EC(50)) values similar to or better than those measured for standard drugs. Substitution of the polyamine for either an alkyl or a polyether linker maintained bioactivity and further alleviated cytotoxicity. Polyamine-linked compounds in which the terminal acridine heterocycle had been replaced with an aza-acridine also maintained acceptable therapeutic indices. The most potent compounds recorded low- to mid-nanomolar EC(50) values against Plasmodium falciparum and Trypanosoma brucei; otherwise, low-micromolar potencies were measured. Importantly, the bioactivity of the library was independent of P. falciparum resistance to chloroquine. Compound bioactivity was a function of neither the potential to bis-intercalate DNA nor the inhibition of trypanothione reductase, an important drug target in trypanosomatid parasites. Our approach illustrates the usefulness of screening focused compound libraries against multiple parasite targets. Some of the bis-acridines identified here may represent useful starting points for further lead optimization.


Subject(s)
Acridines , Antiparasitic Agents , Combinatorial Chemistry Techniques/methods , Eukaryota/drug effects , Schistosoma mansoni/drug effects , Acridines/chemical synthesis , Acridines/chemistry , Acridines/pharmacology , Acridines/toxicity , Animals , Antiparasitic Agents/chemical synthesis , Antiparasitic Agents/chemistry , Antiparasitic Agents/pharmacology , Antiparasitic Agents/toxicity , Eukaryota/classification , Eukaryota/growth & development , HL-60 Cells , Humans , Parasitic Sensitivity Tests , Plasmodium falciparum/drug effects , Polyamines/chemistry , Schistosoma mansoni/growth & development , Structure-Activity Relationship , Trypanosoma brucei brucei/drug effects
15.
J Med Chem ; 45(13): 2695-707, 2002 Jun 20.
Article in English | MEDLINE | ID: mdl-12061873

ABSTRACT

American trypanosomiasis, or Chagas' disease, is the leading cause of heart disease in Latin America. Currently there is an urgent need to develop antitrypanosomal therapy due to the toxicity of existing agents and emerging drug resistance. A novel series of potent thio semicarbazone small-molecule inhibitors of the Trypanosoma cruzi cysteine protease cruzain have been identified. Some of these inhibitors have been shown to be trypanocidal. We initially discovered that 3'-bromopropiophenone thio semicarbazone (1i) inhibited cruzain and could cure mammalian cell cultures infected with T. cruzi. 3'-Bromopropiophenone thio semicarbazone showed no toxicity for mammalian cells at concentrations that were trypanocidal. Following this lead, more than 100 compounds were designed and synthesized. A specific structure-activity relationship (SAR) was established, and many potent analogues with IC(50) values in the low nanomolar range were identified. Eight additional analogues were trypanocidal in a cell culture assay, and this indicates that aryl thio semicarbazone is a productive scaffold for killing the parasites. Kinetic studies show that these are time-dependent inhibitors. Molecular modeling studies of the enzyme-inhibitor complex have led to a proposed mechanism of interaction as well as insight into the SAR of the thio semicarbazone series. The nonpeptide nature of this series, small size, and extremely low cost of production suggest this is a promising direction for the development of new antitrypanosome chemotherapy.


Subject(s)
Cysteine Proteinase Inhibitors/chemical synthesis , Protozoan Proteins/antagonists & inhibitors , Thiosemicarbazones/chemical synthesis , Trypanocidal Agents/chemical synthesis , Trypanosoma cruzi/enzymology , Animals , Cysteine Endopeptidases , Cysteine Proteinase Inhibitors/chemistry , Cysteine Proteinase Inhibitors/pharmacology , Models, Molecular , Structure-Activity Relationship , Thiosemicarbazones/chemistry , Thiosemicarbazones/pharmacology , Trypanocidal Agents/chemistry , Trypanocidal Agents/pharmacology
16.
Medicina (B.Aires) ; 59(supl.2): 171-5, 1999. ilus, tab
Article in Spanish | LILACS | ID: lil-242252

ABSTRACT

El mal de Chagas, endémico en la mayoría de los países de América, causa una alta morbilidad y mortalidad. Aunque evidencias experimentales y clínica muestran la importancia de la quimioterapia tanto en la fase aguda como crónica de la enfermedad, el tratamiento de los pacientes se ve limitado por la toxicidad de las drogas disponibles. En esta revisión se describe el diseño, evolución de péptidos miméticos capaces de interrumpir el ciclo intracelular de T. cruzi y de curar infecciones experimentales agudas en animales de laboratorio. Los péptido-miméticos inhiben especificamente la actividad enzimática de cruzaína, una cisteín proteasa de T. cruzi, y causan alteraciones en el complejo de Golgi y retículo endoplásmico, acumulación de enzima no procesada en cistemas del complejo de Golgi, y disminución de la enzima acumulada en lisosomas. El compuesto más efectivo, N-Pip-F-hF-VSphi, cura infecciones letales agudas en animales experimentales. No se observan lesiones miocárdicas, infiltración linfocitaria, o nidos de amastigotes intracelulares en animales tratados con el compuesto. Estudios toxicológicos y farmacoquinéticos preliminares indican la ausencia de toxicidad asociada a altas dosis y tratamientos prolongados. Los inhibidores de proteasas podrían constituir en el futuro buenas alternativas quimioterapéuticas para el tratamiento del Chagas agudo y crónico.


Subject(s)
Animals , Rats , Antiprotozoal Agents/therapeutic use , Chagas Disease/drug therapy , Cysteine Proteinase Inhibitors/therapeutic use , Acute Disease , Chagas Disease/pathology , Chronic Disease , Cysteine Proteinase Inhibitors/chemistry , Cysteine Proteinase Inhibitors/pharmacology , Disease Models, Animal
17.
Medicina [B.Aires] ; 59(supl.2): 171-5, 1999. ilus, tab
Article in Spanish | BINACIS | ID: bin-15080

ABSTRACT

El mal de Chagas, endémico en la mayoría de los países de América, causa una alta morbilidad y mortalidad. Aunque evidencias experimentales y clínica muestran la importancia de la quimioterapia tanto en la fase aguda como crónica de la enfermedad, el tratamiento de los pacientes se ve limitado por la toxicidad de las drogas disponibles. En esta revisión se describe el diseño, evolución de péptidos miméticos capaces de interrumpir el ciclo intracelular de T. cruzi y de curar infecciones experimentales agudas en animales de laboratorio. Los péptido-miméticos inhiben especificamente la actividad enzimática de cruzaína, una cisteín proteasa de T. cruzi, y causan alteraciones en el complejo de Golgi y retículo endoplásmico, acumulación de enzima no procesada en cistemas del complejo de Golgi, y disminución de la enzima acumulada en lisosomas. El compuesto más efectivo, N-Pip-F-hF-VSphi, cura infecciones letales agudas en animales experimentales. No se observan lesiones miocárdicas, infiltración linfocitaria, o nidos de amastigotes intracelulares en animales tratados con el compuesto. Estudios toxicológicos y farmacoquinéticos preliminares indican la ausencia de toxicidad asociada a altas dosis y tratamientos prolongados. Los inhibidores de proteasas podrían constituir en el futuro buenas alternativas quimioterapéuticas para el tratamiento del Chagas agudo y crónico. (AU)


Subject(s)
Animals , Rats , Chagas Disease/drug therapy , Antiprotozoal Agents/therapeutic use , Cysteine Proteinase Inhibitors/therapeutic use , Disease Models, Animal , Chagas Disease/pathology , Acute Disease , Chronic Disease , Cysteine Proteinase Inhibitors/chemistry , Cysteine Proteinase Inhibitors/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...